Although there are some controversies concerning the measurement of HER2 amplification in breast cancers, it is conventionally accepted that trastuzumab is only effective in a subset of breast cancers, those with elevated HER2 expression as assessed by these diagnostic assays. This evidence concerns the gene ERBB2 and breast cancer.